Baxter International Is Building A Tariff Defense Mechanism With Exemption & Sourcing Tactics But Will It Work? 

Baxter International’s Q1 2025 earnings results reflect a robust performance with notable growth across its operating segments, though not without challenges reflective of the current global economic climate. The company reported a 5% increase in sales from continuing operations, exceeding its initial projections of 3% to 4%. This performance was driven by substantial contributions from all three segments: Medical Products and Therapies (MPT), Healthcare Systems and Technologies (HST), and Pharmaceuticals.